Wang Zhi-Kui, Liu Zhen-Ying, Yu Hai-Bo
Department of Nephrology, Linyi People's Hospital, Linyi 276003, Shandong, China.
Department of Nephrology, Linyi People's Hospital, Linyi 276003, Shandong, China.
Asian Pac J Trop Med. 2015 Jun;8(6):498-501. doi: 10.1016/j.apjtm.2015.05.007. Epub 2015 Jun 25.
To study the protective effect of telmisartan on rats with renal failure and its mechanism.
60 Wistar rats were chosen as study objective, and were divided into 4 groups randomly: 15 in group A (sham operation group), 15 in group B (model group), 15 in group C (telmisartan group) and 15 in group D (telmisartan + GW9962 group). The difference of survival rate, blood-urine biochemical indexes, renal pathological change, and the expression level of PPARγ and nNOS were compared.
After 12 weeks, the survival rate of group A was 93.33% (14/15), that of group B was 46.67% (7/15), that of group C was 86.67% (13/15), that of group D was 60.00% (9/15), and the difference among 4 groups had statistical significance (P < 0.05). After 1 week, the difference of Scr, that of BUN and that of 24 h protein urine among 4 groups was not statistical significant (P > 0.05); after 3 weeks, 6 weeks and 12 weeks, these difference was statistical significant (P < 0.05). The difference of blood-urine biochemical indexes, that of renal pathological change, and that of the expression level of PPARγ and nNOS was statistical significant (P < 0.05).
Telmisartan has protective effect on renal failure caused by 5/6 nephrectomy, which might be relative to the expression level of PPARγ and nNOS.